Literature DB >> 29039420

Kidney cancer: PSMA: a potential therapeutic target in RCC.

Michael A Gorin1, Steven P Rowe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29039420     DOI： 10.1038/nrurol.2017.164

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Authors:  Sophia Spatz; Yuri Tolkach; Klaus Jung; Carsten Stephan; Jonas Busch; Bernhard Ralla; Anja Rabien; Georg Feldmann; Peter Brossart; Ralph A Bundschuh; Hojjat Ahmadzadehfar; Markus Essler; Marieta Toma; Stefan C Müller; Jörg Ellinger; Stefan Hauser; Glen Kristiansen
Journal:  J Urol       Date:  2017-08-19       Impact factor: 7.450

3.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Authors:  Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2016-03-16       Impact factor: 10.057

4.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

5.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668

Review 6.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

7.  Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.

Authors:  Lino M Sawicki; Christian Buchbender; Johannes Boos; Markus Giessing; Johannes Ermert; Christina Antke; Gerald Antoch; Hubertus Hautzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236

8.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Authors:  Richard P Baum; Harshad R Kulkarni; Christiane Schuchardt; Aviral Singh; Martina Wirtz; Stefan Wiessalla; Margret Schottelius; Dirk Mueller; Ingo Klette; Hans-Jürgen Wester
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

Review 9.  Systemic treatment of renal cell cancer: A comprehensive review.

Authors:  Amparo Sánchez-Gastaldo; Emmanuelle Kempf; Aránzazu González Del Alba; Ignacio Duran
Journal:  Cancer Treat Rev       Date:  2017-09-01       Impact factor: 12.111

10.  Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour.

Authors:  Handoo Rhee; John Blazak; Chui Ming Tham; Keng Lim Ng; Benjamin Shepherd; Malcolm Lawson; John Preston; Ian Vela; Paul Thomas; Simon Wood
Journal:  EJNMMI Res       Date:  2016-10-22       Impact factor: 3.138
  10 in total
  4 in total

1.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 2.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

3.  PSMA theragnostics for metastatic castration resistant prostate cancer.

Authors:  Hong Song; Kip E Guja; Andrei Iagaru
Journal:  Transl Oncol       Date:  2022-05-31       Impact factor: 4.803

Review 4.  PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Authors:  Abdul Razik; Chandan Jyoti Das; Sanjay Sharma
Journal:  Indian J Urol       Date:  2018 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.